Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BET for Immune Reconstitution in iNHL/CLL
NCT03823365Phase 1Unknown
- Sponsor
- Papa Giovanni XXIII Hospital
- Start
- Dec 2018
- Primary completion
- Nov 2021
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of blinatumomab in Indolent Non-Hodgkin Lymphoma (INHL) and chronic lymphocytic leukemia (CLL), sponsored by Papa Giovanni XXIII Hospital. Primary endpoint: Number of grade 3 or 4 adverse events possibly related to therapy at 14 days. Status: unknown.
02
Drugs
blinatumomab
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03823365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03823365.